Source comparison
AOD 9604 vs Other Fat-Loss Peptides
AOD 9604 HGH fragment (beta-3 AR lipolysis) Phase 2b failed Minimal $40-80 Semaglutide GLP-1 agonist FDA-approved (14.9% loss) GI (44% nausea) $199-499 Tirzepatide GLP-1/GIP dual agonist FDA-approved (22.5% loss) GI (31% nausea) $299-499 Tesamorelin GHRH analo
This comparison does not assign a generated winner or score.
- AOD 9604
- HGH fragment (beta-3 AR lipolysis)
- Phase 2b failed
- Minimal
- $40-80
- Semaglutide
- GLP-1 agonist
- FDA-approved (14.9% loss)
- GI (44% nausea)
- $199-499
- Tirzepatide
- GLP-1/GIP dual agonist
- FDA-approved (22.5% loss)
- GI (31% nausea)
- $299-499
- Tesamorelin
- GHRH analog (GH release)
- FDA-approved (lipodystrophy)
- Moderate
- $200-400
- CJC-1295/Ipamorelin
- GH secretagogue
- Limited human data
- $100-200
- MOTS-c
- Mitochondrial peptide
- Preclinical only
- Unknown
- $80-150
- AOD 9604 is the lowest-cost option with the weakest clinical evidence. Semaglutide and tirzepatide have FDA approval, large RCTs, and proven 15-22% weight loss. For proven pharmaceutical fat loss, GLP-1 drugs are the clear choice. AOD 9604 remains in the research conversation because of its favorable safety profile and low cost.
- See our best peptides for weight loss guide for a comprehensive comparison.